White House expands coverage for essential diagnostic services

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Centers for Medicare & Medicaid Services and the Departments of Labor and the Treasury issued guidance to enable Americans with private health insurance to get coverage of COVID-19 diagnostic testing and other related services, including antibody testing, at no cost.

Issued on April 11, the guidance implements the recently enacted Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act, which require that private health issuers and employer group health plans cover COVID-19 testing and certain related items and services furnished during the COVID-19 pandemic, with no out-of-pocket expenses.

The guidance requires group health plans and group and individual health insurance to cover diagnostic testing and certain related items and services provided during a medical visit with no cost sharing. This includes urgent care visits, emergency room visits, and in-person or telehealth visits to the doctor’s office that result in an order for or administration of a COVID-19 test.

Covered COVID-19 tests include all FDA-authorized COVID-19 diagnostic tests, COVID-19 diagnostic tests that developers request authorization for on an emergency basis, and COVID-19 diagnostic tests developed in and authorized by states.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login